136 related articles for article (PubMed ID: 37393162)
21. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.
Hakimi AA; Ostrovnaya I; Jacobsen A; Susztak K; Coleman JA; Russo P; Winer AG; Mano R; Sankin AI; Motzer RJ; Voss MH; Offit K; Purdue M; Pomerantz M; Freedman M; Choueiri TK; Hsieh JJ; Klein RJ
Cancer; 2016 Feb; 122(3):402-10. PubMed ID: 26505625
[TBL] [Abstract][Full Text] [Related]
22. Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma.
Flippot R; Mouawad R; Spano JP; Rouprêt M; Compérat E; Bitker MO; Parra J; Vaessen C; Allanic F; Manach Q; Tannir NM; Khayat D; Su X; Malouf GG
Sci Rep; 2017 Aug; 7(1):8540. PubMed ID: 28819235
[TBL] [Abstract][Full Text] [Related]
23. Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate-risk clear cell kidney cancer.
Patel N; Hakansson A; Ohtake S; Muraki P; Proudfout JA; Liu Y; Webber L; Ibarra A; Liu VYT; Davicioni E; Chamie K; Pantuck A; Shuch B
Cancer Med; 2023 Mar; 12(5):6437-6444. PubMed ID: 36397716
[TBL] [Abstract][Full Text] [Related]
24. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
[TBL] [Abstract][Full Text] [Related]
25. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.
White-Al Habeeb NM; Di Meo A; Scorilas A; Rotondo F; Masui O; Seivwright A; Gabril M; Girgis AH; Jewett MA; Yousef GM
Clin Exp Metastasis; 2015 Aug; 32(6):531-41. PubMed ID: 26037892
[TBL] [Abstract][Full Text] [Related]
26. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
27. A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.
Klimov S; Miligy IM; Gertych A; Jiang Y; Toss MS; Rida P; Ellis IO; Green A; Krishnamurti U; Rakha EA; Aneja R
Breast Cancer Res; 2019 Jul; 21(1):83. PubMed ID: 31358020
[TBL] [Abstract][Full Text] [Related]
28. Predicting Recurrence After Radical Surgery for High-Risk Renal Cell Carcinoma: Development and Internal Validation of the "TOWARDS" Score.
Ishiyama Y; Omae K; Kondo T; Yoshida K; Iizuka J; Takagi T
Ann Surg Oncol; 2024 May; 31(5):3513-3522. PubMed ID: 38285306
[TBL] [Abstract][Full Text] [Related]
29. Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma.
Girgis H; Masui O; White NM; Scorilas A; Rotondo F; Seivwright A; Gabril M; Filter ER; Girgis AH; Bjarnason GA; Jewett MA; Evans A; Al-Haddad S; Siu KM; Yousef GM
Mol Cancer; 2014 May; 13():101. PubMed ID: 24885701
[TBL] [Abstract][Full Text] [Related]
30. Development and verification of a nomogram for prediction of recurrence-free survival in clear cell renal cell carcinoma.
Chen Y; Jiang S; Lu Z; Xue D; Xia L; Lu J; Wang H; Xu L; Li L; Li G
J Cell Mol Med; 2020 Jan; 24(2):1245-1255. PubMed ID: 31782902
[TBL] [Abstract][Full Text] [Related]
31. High APOBEC3B expression is a predictor of recurrence in patients with low-risk clear cell renal cell carcinoma.
Xu L; Chang Y; An H; Zhu Y; Yang Y; Xu J
Urol Oncol; 2015 Aug; 33(8):340.e1-8. PubMed ID: 26051357
[TBL] [Abstract][Full Text] [Related]
32. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology.
Pichler M; Hutterer GC; Chromecki TF; Jesche J; Kampel-Kettner K; Rehak P; Pummer K; Zigeuner R
J Urol; 2011 Nov; 186(5):1773-7. PubMed ID: 21944989
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
34. The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-metastatic Clear Cell Renal Cell Carcinoma.
Ohsugi H; Yoshida T; Ohe C; Ikeda J; Sugi M; Kinoshita H; Tsuta K; Matsuda T
Ann Surg Oncol; 2021 Apr; 28(4):2359-2366. PubMed ID: 32940805
[TBL] [Abstract][Full Text] [Related]
35. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
Brooks SA; Brannon AR; Parker JS; Fisher JC; Sen O; Kattan MW; Hakimi AA; Hsieh JJ; Choueiri TK; Tamboli P; Maranchie JK; Hinds P; Miller CR; Nielsen ME; Rathmell WK
Eur Urol; 2014 Jul; 66(1):77-84. PubMed ID: 24613583
[TBL] [Abstract][Full Text] [Related]
36. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
Pagès F; Mlecnik B; Marliot F; Bindea G; Ou FS; Bifulco C; Lugli A; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Angelova M; Vasaturo A; Maby P; Church SE; Angell HK; Lafontaine L; Bruni D; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Meyers JP; Paustian C; Feng Z; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Mușină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Sargent DJ; Fox BA; Galon J
Lancet; 2018 May; 391(10135):2128-2139. PubMed ID: 29754777
[TBL] [Abstract][Full Text] [Related]
37. Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma.
Wang C; Li Y; Chu CM; Zhang XM; Ma J; Huang H; Wang YN; Hong TY; Zhang J; Pan XW; Zheng JC; Jiang N; Hu CY; Ma X; Sun YH; Cui XG
EBioMedicine; 2019 Jan; 39():255-264. PubMed ID: 30558998
[TBL] [Abstract][Full Text] [Related]
38. p21-activated kinase 1 predicts recurrence and survival in patients with non-metastatic clear cell renal cell carcinoma.
Zhu Y; Xu L; An H; Liu W; Wang Z; Xu J
Int J Urol; 2015 May; 22(5):447-53. PubMed ID: 25711487
[TBL] [Abstract][Full Text] [Related]
39. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma.
Wei JH; Haddad A; Wu KJ; Zhao HW; Kapur P; Zhang ZL; Zhao LY; Chen ZH; Zhou YY; Zhou JC; Wang B; Yu YH; Cai MY; Xie D; Liao B; Li CX; Li PX; Wang ZR; Zhou FJ; Shi L; Liu QZ; Gao ZL; He DL; Chen W; Hsieh JT; Li QZ; Margulis V; Luo JH
Nat Commun; 2015 Oct; 6():8699. PubMed ID: 26515236
[TBL] [Abstract][Full Text] [Related]
40. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
